Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +16.07%. A quarter ago, it was expected that this company would post earnings of $0.13 per share when it actually produced earnings of $0.19, delivering a surprise of +46.15%.Over the last four qu ...

Company Performance - Quest Diagnostics (DGX) shares have increased by 14.1% over the past month, reaching a new 52-week high of $207.05 [1] - The stock has gained 18.3% since the beginning of the year, outperforming the Zacks Medical sector's 0.9% gain and the Zacks Medical - Outpatient and Home Healthcare industry's 9.7% return [1] Earnings and Valuation - The company has a strong record of positive earnings surprises, beating the Zacks Consensus Estimate in the last four quarters [2] - In the latest earnings report on February 10, 2026, Quest Diagnostics reported EPS of $2.42, exceeding the consensus estimate of $2.35, and beat the revenue estimate by 2.08% [2] - The stock currently trades at 19.7X current fiscal year EPS estimates, which is a premium compared to the peer industry average of 18.9X [6] - On a trailing cash flow basis, the stock trades at 13.5X versus the peer group's average of 18.8X, with a PEG ratio of 2.59 [6] Zacks Rank and Style Scores - Quest Diagnostics holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts [7] - The company has a Value Score of B, Growth Score of B, and Momentum Score of B, resulting in a combined VGM Score of A [5][8] Industry Comparison - DaVita Inc. (DVA) is a notable peer with a Zacks Rank of 1 (Strong Buy) and a Value Score of A, indicating strong performance in comparison [9] - DaVita Inc. reported earnings that beat consensus estimates by 4.94%, with expected earnings of $14.16 per share on revenue of $14.11 billion for the current fiscal year [10] - Despite the Medical - Outpatient and Home Healthcare industry ranking in the bottom 59% of all industries, there are positive tailwinds for both DGX and DVA [11]

Core Viewpoint - Quest Diagnostics reported quarterly earnings of $2.42 per share, exceeding the Zacks Consensus Estimate of $2.35 per share, and showing an increase from $2.23 per share a year ago, representing an earnings surprise of +2.85% [1] Financial Performance - The company achieved revenues of $2.81 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.08%, compared to $2.62 billion in the same quarter last year [2] - Over the last four quarters, Quest Diagnostics has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - Quest Diagnostics shares have increased approximately 10.2% since the beginning of the year, outperforming the S&P 500's gain of 1.7% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.37 on revenues of $2.75 billion, and for the current fiscal year, it is $10.45 on revenues of $11.35 billion [7] - The trend of estimate revisions for Quest Diagnostics was favorable ahead of the earnings release, which may influence future stock movements [5][6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Quest Diagnostics belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, indicating potential challenges in overall industry performance [8]

Core Viewpoint - Encompass Health (EHC) reported quarterly earnings of $1.46 per share, exceeding the Zacks Consensus Estimate of $1.29 per share, and showing an increase from $1.17 per share a year ago, indicating a positive earnings surprise of +12.95% [1] Financial Performance - The company achieved revenues of $1.54 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.23% and up from $1.41 billion year-over-year [2] - Over the last four quarters, Encompass Health has consistently exceeded consensus EPS estimates and revenue estimates [2] Stock Performance - Encompass Health shares have declined approximately 9.9% since the beginning of the year, contrasting with the S&P 500's gain of 0.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.50 on revenues of $1.58 billion, and for the current fiscal year, it is $5.81 on revenues of $6.44 billion [7] - The trend of earnings estimate revisions for Encompass Health was mixed prior to the earnings release, which may influence future stock performance [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Encompass Health belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Company Overview - Contineum Therapeutics, Inc. (CTNM) is part of the Medical group, which consists of 928 companies and is currently ranked 10 in the Zacks Sector Rank [2] - CTNM has a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for CTNM's full-year earnings has increased by 11.5%, reflecting improved analyst sentiment [4] - Year-to-date, CTNM has achieved a return of approximately 33.1%, significantly outperforming the average return of 3.5% for Medical companies [4] Industry Comparison - CTNM belongs to the Medical - Biomedical and Genetics industry, which includes 449 stocks and is currently ranked 90 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has seen an average gain of 19.4% this year, indicating that CTNM is performing well within its specific industry [6] Additional Comparisons - Another Medical stock, Quest Diagnostics (DGX), has returned 6.7% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Quest Diagnostics is part of the Medical - Outpatient and Home Healthcare industry, which has a lower year-to-date return of 3.6% and is ranked 196 [7]

Core Viewpoint - DaVita HealthCare reported quarterly earnings of $3.4 per share, exceeding the Zacks Consensus Estimate of $3.24 per share, and showing a significant increase from $2.24 per share a year ago, indicating strong financial performance [1] Financial Performance - The company achieved revenues of $3.62 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.69% and up from $3.29 billion in the same quarter last year [2] - Over the last four quarters, DaVita has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] Stock Performance - DaVita HealthCare shares have declined approximately 3.8% since the beginning of the year, contrasting with the S&P 500's gain of 1.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.47 on revenues of $3.32 billion, and for the current fiscal year, it is $12.89 on revenues of $13.9 billion [7] - The trend of earnings estimate revisions prior to the earnings release was mixed, which may influence future stock performance [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which DaVita belongs, is currently ranked in the bottom 20% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Viewpoint - DaVita Inc. is expected to report its fourth-quarter 2025 results on February 2, 2026, with a focus on operational execution and seasonal normalization impacting performance [1][3][6]. Performance Factors - The fourth-quarter performance is anticipated to benefit from improved treatment volumes, a favorable treatment-day mix, and the absence of previous disruptions [3]. - Management has indicated expectations for higher revenue per treatment due to routine rate adjustments, vaccine-related revenues, and the resolution of aged claims [3][4]. - Cost discipline is expected to support results, with ongoing investments in technology and operational efficiency aimed at enhancing productivity despite higher near-term expenses [4][19][20]. Challenges - Elevated mortality rates and higher missed treatment frequencies are likely to continue affecting volume growth [5]. - Variability in payer mix and increased pharmaceutical usage may temper margin expansion [5][21]. Earnings Estimates - The Zacks Consensus Estimate for fourth-quarter 2025 revenues is $3.53 billion, reflecting a 6.9% increase from the prior year [7]. - The consensus estimate for EPS is $3.24, indicating a 44.6% increase from the previous year [7]. Stock Performance - DaVita's shares have decreased by 9.6% over the past three months, underperforming both the Medical - Outpatient and Home Healthcare sector and the broader market [11][15]. - The company currently holds a Zacks Rank of 3, indicating a hold position [10]. Valuation Metrics - DaVita's forward 12-month price-to-sales (P/S) ratio is 0.5X, significantly lower than the industry average of 2.6X [16]. - The company is trading at a discount compared to peers, suggesting a lower price relative to expected sales growth [18]. Long-Term Strategy - DaVita's management emphasizes a long-term strategy focused on improving clinical care, leveraging technology, and maintaining disciplined execution to enhance patient outcomes [19]. - Investments in technology and data analytics are aimed at improving care coordination and operational efficiency, despite short-term cost impacts [20]. - The company's integrated kidney care (IKC) and value-based care initiatives are expected to provide structural earnings visibility over time [21].

Core Viewpoint - Option Care (OPCH) shares experienced an 8.4% increase, closing at $34.75, driven by strong preliminary 2025 results and a significant buyback expansion [1][2]. Financial Performance - The company guided Q4 revenue to be between $1.46 billion and $1.47 billion, with adjusted EPS expected to be between 46 cents and 49 cents [2]. - For 2026, adjusted EPS guidance is projected to be between $1.82 and $1.92, exceeding consensus estimates and indicating strong earnings durability [2]. - The upcoming quarterly earnings are anticipated to be $0.46 per share, reflecting a year-over-year increase of 31.4%, with revenues expected to rise by 8.2% to $1.46 billion [3]. Shareholder Returns - The board increased its share repurchase authorization by $500 million to a total of $1.0 billion, indicating strong confidence in cash flow and serving as a key catalyst for the stock's recent performance [2]. Market Sentiment - Despite the recent stock price increase, the consensus EPS estimate for the quarter has been revised slightly lower over the past 30 days, which may not bode well for future price appreciation [4]. - The stock currently holds a Zacks Rank of 3 (Hold), while another company in the same industry, U.S. Physical Therapy (USPH), has a Zacks Rank of 4 (Sell) [5][6].

Core Viewpoint - DaVita HealthCare is experiencing a decline in stock performance, with a notable focus on its upcoming earnings report which is expected to show significant growth in earnings per share (EPS) and revenue compared to the previous year [1][2]. Company Performance - DaVita HealthCare's stock closed at $111.01, down 3.23% from the previous day, underperforming the S&P 500 and the Dow [1]. - Over the past month, the stock has depreciated by 1.67%, while the Medical sector gained 0.82% and the S&P 500 gained 1.19% [1]. Earnings Expectations - The upcoming earnings report is anticipated to show an EPS of $3.34, reflecting a 49.11% increase year-over-year, with revenue expected to reach $3.53 billion, a 6.99% increase from the same quarter last year [2]. - For the entire fiscal year, earnings are projected at $10.52 per share, indicating an 8.68% increase, while revenue is expected to remain flat at $13.55 billion [3]. Analyst Forecasts - Investors should monitor recent revisions to analyst forecasts, as positive estimate revisions are seen as a favorable indicator for business outlook [3]. - The Zacks Rank system currently rates DaVita HealthCare at 3 (Hold), with the consensus EPS projection remaining unchanged over the past 30 days [5]. Valuation Metrics - DaVita HealthCare has a Forward P/E ratio of 8.9, which is significantly lower than the industry average of 18.1, indicating a potential undervaluation [6]. - The company also has a PEG ratio of 0.71, compared to the industry average of 1.78, suggesting that the stock may be undervalued relative to its expected earnings growth [7]. Industry Context - The Medical - Outpatient and Home Healthcare industry, which includes DaVita HealthCare, holds a Zacks Industry Rank of 59, placing it in the top 25% of over 250 industries [8].

Company Performance - DaVita HealthCare (DVA) closed at $116.51, with a daily increase of +1.14%, outperforming the S&P 500's gain of 0.64% [1] - Over the past month, DVA shares have decreased by 4.2%, underperforming the Medical sector's increase of 2.25% and the S&P 500's increase of 3% [1] Earnings Projections - The upcoming EPS for DaVita HealthCare is projected at $3.34, indicating a significant increase of 49.11% compared to the same quarter last year [2] - Revenue is expected to reach $3.53 billion, reflecting a growth of 6.99% year-over-year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $10.52 per share, representing an increase of 8.68% from the previous year [3] - Revenue for the fiscal year is estimated at $13.55 billion, indicating a growth of 5.75% compared to the prior year [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for DaVita HealthCare should be monitored, as they often reflect short-term business trends [4] - Positive estimate revisions are interpreted as favorable indicators for the business outlook [4] Zacks Rank and Valuation - DaVita HealthCare currently holds a Zacks Rank of 3 (Hold), with the EPS estimate remaining unchanged over the last 30 days [6] - The company is trading at a Forward P/E ratio of 10.95, which is below the industry average of 19.65 [7] - DaVita has a PEG ratio of 0.87, compared to the industry average PEG ratio of 1.96 [7] Industry Context - The Medical - Outpatient and Home Healthcare industry ranks in the top 22% of all industries, with a current Zacks Industry Rank of 53 [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]